BIOC - Biocept, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

0.2292

-0.0088 (-3.6975%)

At close: 3:59PM EDT

Stock chart is not supported by your current browser

Previous Close	0.2380
Open	0.2337
Bid	0.2150 x 1000
Ask	0.2400 x 7000
Day's Range	0.2156 - 0.2400
52 Week Range	0.2156 - 1.9000
Volume	1,194,550
Avg. Volume	2,818,748

Market Cap	15.594M
Beta	0.31
PE Ratio (TTM)	N/A
EPS (TTM)	-0.8680
Earnings Date	May 9, 2018 - May 14, 2018
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	0.83

Trade prices are not sourced from all markets

All

News

Press Releases

PR Newswire20 days ago
Biocept to Webcast Presentation at the 7th Annual MicroCap Conference
A live webcast of the corporate presentation will be available on the Company's website at ir.biocept.com. Mr. Nall will also cohost the Cancer Research Roundtable, being held April 9 at 9:30 a.m. Eastern time. The roundtable will feature CEOs from leading companies in the cancer research field discussing innovative solutions for patients with cancer.
ACCESSWIRE20 days ago
Free Post Earnings Research Report: Exact Sciences’ Quarterly Revenues Jumped 148.02%
Stock Monitor: Biocept Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 6, 2018 / Active-Investors.com has just released a free earnings report on Exact Sciences Corp. (NASDAQ: EXAS ) ("EXAS"). ...
PR Newswire23 days ago
Biocept to Present at the 7th Annual MicroCap Conference
Company to also co-host roundtable discussion SAN DIEGO , April 3, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians ...
PR Newswire28 days ago
Biocept Obtains Patent for its Target Selector Molecular Biomarker Technology in China
SAN DIEGO, March 29, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the issuance of Chinese Patent No. ZL201280032293.0, entitled METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIANTS. This is the third issued patent for Biocept's Target Selector™ assays for molecular analysis using real-time PCR, Sanger sequencing and next-generation sequencing (NGS).
PR Newswire29 days ago
Biocept Reports 2017 Fourth Quarter and Full Year Financial Results
2017 revenues increased 57% due to higher reimbursement for Target Selector™ liquid biopsy tests and the impact of conversion to accrual-based revenue recognition Company to host conference call at 4:30 ...
ACCESSWIRE29 days ago
Biocept, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 28, 2018 / Biocept, Inc. (NASDAQ: BIOC ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 28, 2018 at 4:30 PM Eastern Time. To listen ...
ACCESSWIRE29 days ago
Biocept Inc, Liquid Biopsy is Coming, Analysts Review, Biopsy Market and Upcoming Milestones
NEW YORK, NY / ACCESSWIRE / March 28, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
PR Newswire29 days ago
Biocept and Thermo Fisher Scientific Enter into Technology and Commercial Collaboration
Collaboration plans to establish Biocept as Thermo Fisher Center of Excellence for liquid biopsy and to pursue commercial opportunities in both pharmaceutical and clinical markets SAN DIEGO , March 28, ...
PR Newswirelast month
Biocept to Present Recent Advances in Biomarker Identification from Liquid Biopsies at GTCbio's 11th Biomarker Summit
SAN DIEGO , March 20, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to ...
PR Newswirelast month
Biocept's Target Selector Platform Featured in Two Poster Presentations at the 2018 American Association for Cancer Research Annual Meeting
SAN DIEGO, March 15, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that two abstracts have been accepted for poster presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting being held April 14-18, 2018 in Chicago at McCormick Place North/South.
PR Newswirelast month
Biocept to Release 2017 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 28, 2018
SAN DIEGO , March 12, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable ...
PR Newswire2 months ago
Biocept to Present at the 30th Annual ROTH Conference
SAN DIEGO , March 6, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve ...
PR Newswire3 months ago
Biocept Receives Additional Patent Issuances in Three Major International Territories for its Target Selector Platform
SAN DIEGO, Feb. 5, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the issuance of patents in Europe, Japan and Hong Kong for its core Target Selector™ liquid biopsy technology. In Japan, Biocept's patent no. 6234817 is entitled METHODS AND REAGENTS FOR SIGNAL AMPLIFICATION, and in Europe, Biocept's patent no. 2995953 is entitled DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS.
ACCESSWIRE3 months ago
Dawson James Securities Announces Closing of Approximately $14.78M Public Offering for Biocept, Inc.
BOCA RATON, FL / ACCESSWIRE / January 31, 2018 / Dawson James Securities, Inc. in conjunction with Biocept, Inc. (NASDAQ: BIOC) announced today the closing of a "best efforts" public offering ...
PR Newswire3 months ago
Biocept Announces Closing of $14.8 Million Public Offering of 32,854,606 Shares of Common Stock and Warrants to Purchase 32,854,606 Shares of Common Stock
Biocept received proceeds from the offering of approximately $13.3 million, after deducting the applicable placement agents' fee and estimated offering expenses payable by Biocept. Biocept intends to use the proceeds for general corporate purposes, to fund ongoing operations and expansion of its business, and to service its existing indebtedness.
PR Newswire3 months ago
Biocept Comments on Updated Consensus Medical Guidelines Recommending Liquid Biopsy for Profiling of Tumor Biomarkers to Assist with the Treatment of Patients with Lung Cancer
SAN DIEGO, Jan. 30, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, comments on the recently updated consensus clinical guidelines from four major societies considered authorities in pathology and oncology that recommend the use of liquid biopsy testing for patients newly diagnosed with lung cancer as well as those progressing on first-line targeted therapy. The evidence-based guidelines were developed in collaboration by the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASCL), the Association for Molecular Pathology (AMP) and the American Society for Investigative Pathology (ASIP), and jointly published in the Archives of Pathology & Laboratory Medicine, Journal of Thoracic Oncology and The Journal of Molecular Diagnostics.
SmarterAnalyst3 months ago
Biocept Inc (BIOC) Dilutes Shareholders a Second Time in Two Months
Biocept Inc (NASDAQ:BIOC) shares are tumbling nearly 24% in Friday's trading session. The double-digit fall today is occurring in the face of a sizable secondary offering. Specifically, the company announced an underwritten public offering of 33,333,333 of its common shares. Each share of common stock is being sold together with a common warrant at a combined effective price to the public of $0.45. The warrants will be exercisable immediately at an exercise price of $0.50 per share and will expire five years from the date of issuance.
PR Newswire3 months ago
Biocept Announces Pricing of $15.0 Million Public Offering of 33,333,333 Shares of Common Stock and Warrants to Purchase 33,333,333 Shares of Common Stock
Biocept is also offering, in lieu of purchasing common stock, Series A convertible preferred stock, to those purchasers whose purchase of common stock in the offering would otherwise result in such purchaser beneficially owning more than 4.99% of Biocept's outstanding common stock immediately following the consummation of the offering. The gross proceeds to Biocept from this offering are expected to be approximately up to $15.0 million, before deducting the placement agents' fee and estimated offering expenses payable by Biocept.
24/7 Wall St.3 months ago
Colony NorthStar, Kimco Realty Slide into Wednesday’s 52-Week Low Club
Colony NorthStar, Kimco Realty, Clean Energy Fuels, and Biocept all posted new 52-week lows Wednesday.
Associated Press3 months ago
Scientists seek super-shot for flu 100 years after pandemic
WASHINGTON (AP) — The descriptions are haunting.
PR Newswire4 months ago
Biocept Study Shows Incorporation of Thermo Fisher QuantStudio 5 PCR Instrument into Target Selector Platform Improves Sensitivity and Specificity in Detection of Lung Cancer Biomarkers
SAN DIEGO, Jan. 9, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that incorporation of the Thermo Fisher QuantStudio5 (QS5) real-time PCR instrument into the Company's Target Selector™ ctDNA lung cancer assays improves detection of key lung cancer mutations. Data from 3,000 samples analyzed using Biocept's liquid biopsy assays for EGFR, BRAF and KRAS mutations demonstrated single mutant copy detection on the QS5 platform with more than 99% sensitivity and more than 99% specificity.
PR Newswire4 months ago
Biocept Obtains Patent in Australia for its Molecular Biomarker Technology For the Detection of Cancer-Associated Mutations in Blood, Tissue, and Other Biological Sources
SAN DIEGO, Jan. 4, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the issuance of Australian Patent No. 2012250516, entitled METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIANTS. This is the second issued patent for Biocept's Target Selector™ assays for molecular analysis using real-time PCR, Sanger sequencing and next generation sequencing (NGS).
PR Newswire4 months ago
Biocept Signs In-Network Provider Agreement with Wellmark Blue Cross Blue Shield Expanding Coverage for its Target Selector Platform in Iowa and South Dakota
SAN DIEGO, Dec. 18, 2017 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has signed an in-network provider agreement with Wellmark, Inc., the largest health insurer in Iowa and South Dakota.